Literature DB >> 11583166

Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidase.

J Usta1, S El Bawab, P Roddy, Z M Szulc, A Hannun, A Bielawska.   

Abstract

The effects of structural analogues of ceramide on rat brain mitochondrial ceramidase (mt-CDase) were investigated. Design of target compounds was mainly based on modifications of the key elements in ceramide and sphingosine, including stereochemistry, the primary and secondary hydroxyl groups, the trans double bond in the sphingosine backbone, and the amide bond. Mt-CDase was inhibited by (1) all stereoisomers of D-erythro-ceramide (D-e-Cer) with an IC50 of 0.11, 0.21, and 0.26 mol % for the L-threo, D-threo, and L-erythro isomers, respectively; (2) all stereoisomers of sphingosine with IC50 ranging from 0.04 to 0.14 mol %, N-methyl-D-erythro-sphingosine (N-Me-Sph, IC50 0.13 mol %); and (3) D-erythro-urea-C16-ceramide (C16-urea-Cer IC50 0.33 mol %). The enzyme was not inhibited by N-methyl ceramide (N-Me-C16-Cer), 1-O-methyl ceramide (1-O-Me-C16-Cer), 3-O-methyl ceramide (3-O-Me-C16-Cer), cis-D-erythro ceramide (cis-D-e-C16-Cer) and 3-O-methyl-D-erythro-sphingosine (3-O-Me-Sph). It was less potently inhibited by D-erythro-sphinganine (D-e-dh-Sph, IC50 0.20 mol %), D-erythro-dehydro sphingosine (D-e-deh-Sph, IC50 0.25 mol %), (2S)-3-keto-sphinganine (3-keto-dh-Sph, IC50 0.34 mol %), (2S) 3-keto-ceramide (3-keto-C16-Cer, IC50 0.60 mol %), and ceramine (C18-ceramine, IC50 0.62 mol %), 1-O-methyl-D-erythro-sphingosine (1-O-Me-Sph), cis-D-erythro-sphingosine (cis-D-e-Sph), (2S)-3-ketosphingosine (3-keto-Sph), (2S)-3-keto-dehyrosphingosine (3-keto-deh-Sph), and N,N-dimethyl-D-erythrosphingosine (N,N-diMe-Sph) were weak inhibitors whereas ceramide-1-phosphate (Cer-1-P) and sphingosine-1-phosphate (Sph-1-P) stimulated the enzyme. Thus, for inhibition, the enzyme requires the primary and secondary hydroxyl groups, the C4-C5 double bond, the trans configuration of this double bond, and the NH-protons from either the amide of ceramide or the amine of sphingosine. Therefore, these results provide important information on the requirements for ceramide-enzyme interaction, and they suggest that ligand interaction with the enzyme occurs in a high affinity low specificity manner, in contrast to catalysis which is highly specific for D-erythro-ceramide (D-e-Cer) but occurs with a lower affinity. In addition, this study identifies two competitive inhibitors of mt-CDase; urea-ceramide (C16-urea-Cer) and ceramine (C18-ceramine) that may be further developed and used to understand the mechanism of mt-CDase in vitro and in biologic responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583166     DOI: 10.1021/bi010535k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

2.  Synthesis and bioevaluation of omega-N-amino analogs of B13.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Nalini Mayroo; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2009-01-31       Impact factor: 3.641

3.  Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Jason S Pierce; Barbara Rembiesa; Silva Terzieva; Cungui Mao; Ruijuan Xu; Bill Wu; Christopher J Clarke; Benjamin Newcomb; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2014-10-22       Impact factor: 3.641

4.  Ceramide channels: influence of molecular structure on channel formation in membranes.

Authors:  Meenu N Perera; Vidyaramanan Ganesan; Leah J Siskind; Zdzislaw M Szulc; Jacek Bielawski; Alicja Bielawska; Robert Bittman; Marco Colombini
Journal:  Biochim Biophys Acta       Date:  2012-02-15

Review 5.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

6.  Novel pathway of ceramide production in mitochondria: thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA.

Authors:  Sergei A Novgorodov; Bill X Wu; Tatyana I Gudz; Jacek Bielawski; Tatiana V Ovchinnikova; Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

Review 7.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

8.  Role of Drosophila alkaline ceramidase (Dacer) in Drosophila development and longevity.

Authors:  Qiong Yang; Zhong-Jun Gong; Ying Zhou; Jing-Qun Yuan; Jiaan Cheng; Lin Tian; Sheng Li; Xin-Da Lin; Ruijuan Xu; Zeng-Rong Zhu; Cungui Mao
Journal:  Cell Mol Life Sci       Date:  2010-01-30       Impact factor: 9.261

9.  Substrate specificity, membrane topology, and activity regulation of human alkaline ceramidase 2 (ACER2).

Authors:  Wei Sun; Junfei Jin; Ruijuan Xu; Wei Hu; Zdzislaw M Szulc; Jacek Bielawski; Lina M Obeid; Cungui Mao
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

10.  Role of neutral ceramidase in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Toshihiko Kawamori; Masayuki Wada; Ashley J Snider; Jean-Philip Truman; Bill X Wu; Hideki Furuya; Christopher J Clarke; Agnieszka B Bialkowska; Amr Ghaleb; Vincent W Yang; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2016-09-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.